These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16565237)

  • 1. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial.
    Barnett A
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S132-5. PubMed ID: 16565237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.
    Barnett AH
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S42-9. PubMed ID: 15868119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
    N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of loss of renal function over time in patients with diabetic nephropathy.
    Barnett A
    Am J Med; 2006 May; 119(5 Suppl 1):S40-7. PubMed ID: 16563947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.
    Nakamura T; Fujiwara N; Kawagoe Y; Sugaya T; Ueda Y; Koide H
    Eur J Clin Invest; 2010 Sep; 40(9):790-6. PubMed ID: 20584070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of proteinuria with angiotensin receptor blockers.
    Galle J
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S36-43. PubMed ID: 18580865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.
    Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S
    J Int Med Res; 2005; 33(6):677-86. PubMed ID: 16372586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In the DETAIL. Kidney protection in manifestations of microalbuminuria].
    MMW Fortschr Med; 2006 Jun; 148(26):51. PubMed ID: 16875382
    [No Abstract]   [Full Text] [Related]  

  • 10. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.
    Rippin J; Bain SC; Barnett AH;
    J Diabetes Complications; 2002; 16(3):195-200. PubMed ID: 12015188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan in incipient and overt diabetic renal disease.
    Schmieder RE; Bakris G; Weir MR
    J Nephrol; 2011; 24(3):263-73. PubMed ID: 21374585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.
    Ravid M; Lang R; Rachmani R; Lishner M
    Arch Intern Med; 1996 Feb; 156(3):286-9. PubMed ID: 8572838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of telmisartan on renal outcomes: a randomized trial.
    Mann JF; Schmieder RE; Dyal L; McQueen MJ; Schumacher H; Pogue J; Wang X; Probstfield JL; Avezum A; Cardona-Munoz E; Dagenais GR; Diaz R; Fodor G; Maillon JM; Rydén L; Yu CM; Teo KK; Yusuf S;
    Ann Intern Med; 2009 Jul; 151(1):1-10, W1-2. PubMed ID: 19451556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diabetes and Nephropathy: ACE inhibitor for type 1, AT1 blocker for type 2].
    Zidek W
    MMW Fortschr Med; 2004 Oct; 146(42):51-2. PubMed ID: 15536706
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
    Cao Z; Cooper ME
    Acta Diabetol; 2012 Aug; 49(4):243-54. PubMed ID: 21947383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?
    Schmieder RE
    J Hypertens Suppl; 2006 Apr; 24(2):S31-5. PubMed ID: 16601559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
    Chan JC; Ko GT; Leung DH; Cheung RC; Cheung MY; So WY; Swaminathan R; Nicholls MG; Critchley JA; Cockram CS
    Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE-I and ARBs in early diabetic nephropathy.
    Mauer M; Zinman B; Gardiner R; Drummond KN; Suissa S; Donnelly SM; Strand TD; Kramer MS; Klein R; Sinaiko AR
    J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):262-9. PubMed ID: 12584670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.